BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 33359054)

  • 1. Molecular analysis of EUS-acquired pancreatic cyst fluid for KRAS and GNAS mutations for diagnosis of intraductal papillary mucinous neoplasia and mucinous cystic lesions: a systematic review and meta-analysis.
    McCarty TR; Paleti S; Rustagi T
    Gastrointest Endosc; 2021 May; 93(5):1019-1033.e5. PubMed ID: 33359054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of adding GNAS testing to pancreatic cyst fluid KRAS and carcinoembryonic antigen analysis for the diagnosis of intraductal papillary mucinous neoplasms.
    Kadayifci A; Atar M; Wang JL; Forcione DG; Casey BW; Pitman MB; Brugge WR
    Dig Endosc; 2017 Jan; 29(1):111-117. PubMed ID: 27514845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative GNAS and KRAS testing in the diagnosis of pancreatic mucinous cysts.
    Singhi AD; Nikiforova MN; Fasanella KE; McGrath KM; Pai RK; Ohori NP; Bartholow TL; Brand RE; Chennat JS; Lu X; Papachristou GI; Slivka A; Zeh HJ; Zureikat AH; Lee KK; Tsung A; Mantha GS; Khalid A
    Clin Cancer Res; 2014 Aug; 20(16):4381-9. PubMed ID: 24938521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative next-generation sequencing of pancreatic cyst fluid is highly accurate in cyst classification and detection of advanced neoplasia.
    Singhi AD; McGrath K; Brand RE; Khalid A; Zeh HJ; Chennat JS; Fasanella KE; Papachristou GI; Slivka A; Bartlett DL; Dasyam AK; Hogg M; Lee KK; Marsh JW; Monaco SE; Ohori NP; Pingpank JF; Tsung A; Zureikat AH; Wald AI; Nikiforova MN
    Gut; 2018 Dec; 67(12):2131-2141. PubMed ID: 28970292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Impact of KRAS and GNAS Analysis Added to CEA and Cytology in Pancreatic Cystic Fluid Obtained by EUS-FNA.
    Faias S; Duarte M; Albuquerque C; da Silva JP; Fonseca R; Roque R; Dias Pereira A; Chaves P; Cravo M
    Dig Dis Sci; 2018 Sep; 63(9):2351-2361. PubMed ID: 29796909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KRAS/GNAS-testing by highly sensitive deep targeted next generation sequencing improves the endoscopic ultrasound-guided workup of suspected mucinous neoplasms of the pancreas.
    Schmitz D; Kazdal D; Allgäuer M; Trunk M; Vornhusen S; Nahm AM; Doll M; Weingärtner S; Endris V; Penzel R; Kirchner M; Brandt R; Neumann O; Sültmann H; Budczies J; Kienle P; Magdeburg R; Hetjens S; Schirmacher P; Bergmann F; Rudi J; Stenzinger A; Volckmar AL
    Genes Chromosomes Cancer; 2021 Jul; 60(7):489-497. PubMed ID: 33686791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pancreatic cyst fluid glucose in differentiating mucinous from nonmucinous pancreatic cysts: a systematic review and meta-analysis.
    McCarty TR; Garg R; Rustagi T
    Gastrointest Endosc; 2021 Oct; 94(4):698-712.e6. PubMed ID: 33964311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of next-generation sequencing on the clinical diagnosis of pancreatic cysts.
    Jones M; Zheng Z; Wang J; Dudley J; Albanese E; Kadayifci A; Dias-Santagata D; Le L; Brugge WR; Fernandez-del Castillo C; Mino-Kenudson M; Iafrate AJ; Pitman MB
    Gastrointest Endosc; 2016 Jan; 83(1):140-8. PubMed ID: 26253016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of the RAS pathway through uncommon BRAF mutations in mucinous pancreatic cysts without KRAS mutation.
    Ren R; Krishna SG; Chen W; Frankel WL; Shen R; Zhao W; Avenarius MR; Garee J; Caruthers S; Jones D
    Mod Pathol; 2021 Feb; 34(2):438-444. PubMed ID: 32792597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lower cyst fluid carcinoembryonic antigen cutoff is helpful in the differential diagnosis of mucinous versus non-mucinous pancreatic cysts.
    Sharma RK; Bush N; Rana SS; Srinivasan R; Nada R; Gupta R; Rana S; Singh T
    Indian J Gastroenterol; 2022 Aug; 41(4):397-404. PubMed ID: 36057043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational Mosaics of Cell-Free DNA from Pancreatic Cyst Fluids.
    Paziewska A; Polkowski M; Goryca K; Karczmarski J; Wiechowska-Kozlowska A; Dabrowska M; Mikula M; Ostrowski J
    Dig Dis Sci; 2020 Aug; 65(8):2294-2301. PubMed ID: 31925676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development.
    Wu J; Matthaei H; Maitra A; Dal Molin M; Wood LD; Eshleman JR; Goggins M; Canto MI; Schulick RD; Edil BH; Wolfgang CL; Klein AP; Diaz LA; Allen PJ; Schmidt CM; Kinzler KW; Papadopoulos N; Hruban RH; Vogelstein B
    Sci Transl Med; 2011 Jul; 3(92):92ra66. PubMed ID: 21775669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. American Gastroenterological Association guidelines are inaccurate in detecting pancreatic cysts with advanced neoplasia: a clinicopathologic study of 225 patients with supporting molecular data.
    Singhi AD; Zeh HJ; Brand RE; Nikiforova MN; Chennat JS; Fasanella KE; Khalid A; Papachristou GI; Slivka A; Hogg M; Lee KK; Tsung A; Zureikat AH; McGrath K
    Gastrointest Endosc; 2016 Jun; 83(6):1107-1117.e2. PubMed ID: 26709110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activating mutations of GNAS and KRAS in cystic fluid can help detect intraductal papillary mucinous neoplasms of the pancreas.
    Frampton AE; Stebbing J; Gall TM; Silver B; Jiao LR; Krell J
    Expert Rev Mol Diagn; 2015 Mar; 15(3):325-8. PubMed ID: 25656048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Next generation sequencing of the cellular and liquid fraction of pancreatic cyst fluid supports discrimination of IPMN from pseudocysts and reveals cases with multiple mutated driver clones: First findings from the prospective ZYSTEUS biomarker study.
    Volckmar AL; Endris V; Gaida MM; Leichsenring J; Stögbauer F; Allgäuer M; von Winterfeld M; Penzel R; Kirchner M; Brandt R; Neumann O; Sültmann H; Schirmacher P; Rudi J; Schmitz D; Stenzinger A
    Genes Chromosomes Cancer; 2019 Jan; 58(1):3-11. PubMed ID: 30230086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical assessment of the GNAS mutation status in patients with intraductal papillary mucinous neoplasm of the pancreas.
    Ohtsuka T; Tomosugi T; Kimura R; Nakamura S; Miyasaka Y; Nakata K; Mori Y; Morita M; Torata N; Shindo K; Ohuchida K; Nakamura M
    Surg Today; 2019 Nov; 49(11):887-893. PubMed ID: 30879148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GNAS
    Ideno N; Yamaguchi H; Ghosh B; Gupta S; Okumura T; Steffen DJ; Fisher CG; Wood LD; Singhi AD; Nakamura M; Gutkind JS; Maitra A
    Gastroenterology; 2018 Nov; 155(5):1593-1607.e12. PubMed ID: 30142336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GNAS sequencing identifies IPMN-specific mutations in a subgroup of diminutive pancreatic cysts referred to as "incipient IPMNs".
    Matthaei H; Wu J; Dal Molin M; Shi C; Perner S; Kristiansen G; Lingohr P; Kalff JC; Wolfgang CL; Kinzler KW; Vogelstein B; Maitra A; Hruban RH
    Am J Surg Pathol; 2014 Mar; 38(3):360-3. PubMed ID: 24525507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GNAS(R201H) and Kras(G12D) cooperate to promote murine pancreatic tumorigenesis recapitulating human intraductal papillary mucinous neoplasm.
    Taki K; Ohmuraya M; Tanji E; Komatsu H; Hashimoto D; Semba K; Araki K; Kawaguchi Y; Baba H; Furukawa T
    Oncogene; 2016 May; 35(18):2407-12. PubMed ID: 26257060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GNAS but Not Extended RAS Mutations Spectrum are Associated with a Better Prognosis in Intraductal Pancreatic Mucinous Neoplasms.
    Gaujoux S; Parvanescu A; Cesaretti M; Silve C; Bieche I; Rebours V; Lévy P; Sauvanet A; Cros J
    Ann Surg Oncol; 2019 Aug; 26(8):2640-2650. PubMed ID: 31025231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.